SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Gajra A, Newman N, Gamble GP, et al. Impact of tumor size on survival in stage IA non-small cell lung cancer: a case for subdividing Stage IA disease. Lung Cancer. 2003; 42: 5157.
  • 2
    Qiao X, Tullgren O, Lax I, et al. The role of radiotherapy in treatment of stage I non-small cell lung cancer. Lung Cancer. 2003; 41: 111.
  • 3
    Curran W, Scott CB, Langer CJ, et al. Long-term benefit is observed in a Phase III comparison of sequential vs. concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol. 2003; 22: 621.
  • 4
    Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients [see comments]. J Natl Cancer Inst. 1991; 83: 417423.
  • 5
    Perez CA, Pajak TF, Rubin P. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Cancer. 1987; 59: 18741881.
  • 6
    Armstrong JG, Burman C, Leibel SA, et al. Three-dimensional conformal radiation therapy may improve the therapeutic ratio of high dose radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys. 1993; 26: 685689.
  • 7
    Mohan R. Three-dimensional radiation treatment planning. Australas Phys Eng Sci Med. 1989; 12: 7391.
  • 8
    Armstrong J, Raben A, Zelefsky M, et al. Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer. Radiother Oncol. 1997; 44: 1722.
  • 9
    Mohan R. Dose computations for three-dimensional radiation treatment planning. Australas Phys Eng Sci Med. 1989; 12: 241251.
  • 10
    Mohan R, Barest G, Brewster LJ, et al. A comprehensive three-dimensional radiation treatment planning system. Int J Radiat Oncol Biol Phys. 1988; 15: 481495.
  • 11
    Rosenzweig KE, Amols H, Ling CC. New radiotherapy technologies. Semin Surg Oncol. 2003; 21: 190195.
  • 12
    Lyman JT. Complication probability as assessed from dose-volume histograms. Radiat Res. 1985; 8(Suppl): S13S19.
  • 13
    Kutcher GJ, Burman C, Brewster L, et al. Histogram reduction method for calculating complication probabilities for three-dimensional treatment planning evaluations. Int J Radiat Oncol Biol Phys. 1991; 21: 137146.
  • 14
    Withers HR, Taylor JMG, Maciejewski B. Treatment volume and tissue tolerance. Int J Radiat Oncol Biol Phys. 1988; 14: 751759.
  • 15
    Yorke ED, Jackson A, Rosenzweig KE, et al. Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2002; 54(2 SU): 329339.
  • 16
    Hayman JA, Martel MK, Ten Haken RK, et al. Dose escalation in non-small cell lung cancer (NSCLC) using conformal 3-dimensional radiation therapy (3DCRT): update of a Phase I trial [abstract]. Proc Am Soc Clin Oncol. 1999; 18: 459a.
  • 17
    Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995; 31: 13411346.
  • 18
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 19
    Graham MV, Purdy JA, Harms W, et al. Survival and prognostic factors of non-small cell lung cancer (NSCLC) patients treated with definitive three-dimensional (3D) radiation therapy [abstract]. Int J Radiat Oncol Biol Phys. 1998; 42(1S): 166.
  • 20
    Emami B. Three-dimensional conformal radiation therapy in bronchogenic carcinoma. Semin Radiat Oncol. 1996; 6: 9297.
  • 21
    Schaake-Koning C. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med. 1992; 326: 524530.
  • 22
    Marks LB, Munley MT, Bentel GC, et al. Physical and biological predictors of changes in whole-lung function following thoracic irradiation [see comments]. Int J Radiat Oncol Biol Phys. 1997; 39: 563570.
  • 23
    Kwa SL, Lebesque JV, Theuws JC, et al. Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys. 1998; 42: 19.
  • 24
    Lawrence TS, Hayman JA, Martel M, et al. Regarding predicting [letter]. Int J Radiat Oncol Biol Phys. 1998; 41: 972.
  • 25
    Hayman JA, Martel MK, Ten Haken RK, et al. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a Phase I trial. J Clin Oncol. 2001; 19: 127136.
  • 26
    Bradley JD, Graham MV, Winter KW, et al. Acute and late toxicity results of RTOG 9311: a dose escalation study using 3D conformal radiation therapy in patients with inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2003; 57: S137S138.
  • 27
    Belderbos JS, De Jaeger K, Heemsbergen WD, et al. First results of a Phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy. Radiother Oncol. 2003; 66: 119126.
  • 28
    Graham MV, Winter K, Purdy JA, et al. Preliminary results of an RTOG trial (RTOG 9311), a dose escalation study using 3d conformal radiation therapy in patients with inoperable nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys. 2001; 51(3S): 1920.
  • 29
    Onishi H, Araki T, Shirato H, et. al. Stereotactic hypofractionated high-dose irradiation for Stage I non-small cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer. 2004: 16231631.